Takeda Pharmaceutical (TAK) Common Equity (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Common Equity of $47.4 billion for Q2 2026, little changed year-over-year from $47.5 billion in Q2 2025, and little changed quarter-over-quarter from $47.4 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Common Equity (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Common Equity history runs 10 years deep, the most recent figure standing at $47.4 billion for Q2 2026.
- In Q2 2026, Common Equity changed 0.06% year-over-year to $47.4 billion; the TTM figure through Jun 2026 stood at $47.4 billion (changed 0.06% YoY), while the FY2026 annual figure was $49.4 billion, up 8.42% from the prior year.
- Common Equity for Q2 2026 stood at $47.4 billion, roughly flat from $47.4 billion in the prior quarter.
- The five-year high for Common Equity was $50.5 billion in Q2 2023, with the low at $43.7 billion in Q4 2022.
- The 5-year median for Common Equity is $48.6 billion (2022), against an average of $48.1 billion.
- The sharpest annual moves came in 2024 and 2025: Common Equity advanced 6.99% in 2024, then decreased 7.39% in 2025.
- Takeda Pharmaceutical's Common Equity stood at $43.7 billion in 2022, then advanced by 4.34% to $45.6 billion in 2023, then rose by 6.99% to $48.8 billion in 2024, then rose by 1.78% to $49.7 billion in 2025, then dropped by 4.52% to $47.4 billion in 2026.
- Business Quant data shows TAK's Common Equity at $47.4 billion in Q2 2026, $47.4 billion in Q1 2026, and $49.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | 4.05 Bn |
| 10 | Alkermes | 8.20 Bn | 7.54 Bn | 397.90 Mn | 1.81 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.42 Bn |
| Mar 31, 2026 | 47.38 Bn |
| Dec 31, 2025 | 49.67 Bn |
| Sep 30, 2025 | 48.40 Bn |
| Jun 30, 2025 | 47.45 Bn |
| Mar 31, 2025 | 45.46 Bn |
| Dec 31, 2024 | 48.80 Bn |
| Jun 30, 2024 | 50.10 Bn |
| Mar 31, 2024 | 49.08 Bn |
| Dec 31, 2023 | 45.62 Bn |
| Sep 30, 2023 | 48.96 Bn |
| Jun 30, 2023 | 50.51 Bn |
| Mar 31, 2023 | 48.04 Bn |
| Dec 31, 2022 | 43.72 Bn |
| Sep 30, 2022 | 48.61 Bn |
| Jun 30, 2022 | 48.85 Bn |
| Mar 31, 2022 | 48.92 Bn |
| Dec 31, 2021 | 46.91 Bn |
| Sep 30, 2021 | 48.37 Bn |
| Jun 30, 2021 | 48.42 Bn |